Colgate management
This article was originally published in The Tan Sheet
Executive Summary
Chief Operating Officer Ian Cook will succeed President William Shanahan upon his retirement Sept. 30, the firm reports. Colgate announced the appointment earlier this year, signaling Cook was a likely contender to replace CEO Reuben Mark, who said in 2004 he planned to step down in two to four years ("The Tan Sheet" Feb. 9, 2004, p. 7). Cook will retain his COO title. Separately, Colgate released its second quarter results July 27. Oral care, personal care and home care sales grew 11% to $2.46 bil., and operating profit in the segment was up 4% to $527.4 mil. Net sales for the quarter grew 10.5% to $2.84 bil., but net income including restructuring charges fell 8% to $342.9 mil...
You may also be interested in...
Colgate President Cook Slated For CEO Post After Mark’s 2007 Retirement
Colgate-Palmolive President and COO Ian Cook will take over the chief executive position after current Chairman and CEO Reuben Mark retires in 2007, according to Mark
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.